Brar Savtaj Singh, Manns Braden J
Crit Care. 2007;11(5):164. doi: 10.1186/cc6090.
The authors offer a commentary on the study by Dhainaut et al. on the cost-effectiveness of activated protein C in severe sepsis. Using data from "real world" conditions, the results of this economic evaluation are consistent with previous analyses, and highlight the need for "real world" investigations of new health technologies in critical care.
作者们对Dhainaut等人关于活化蛋白C在严重脓毒症中成本效益的研究进行了评论。利用“现实世界”条件下的数据，这项经济评估的结果与之前的分析一致，并突出了对重症监护中新卫生技术进行“现实世界”调查的必要性。
